7th November, 2023, Ahmedabad, India : Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2023.
Key Financial Highlights
Q2 FY24 Highlights
- Revenue from operations at Rs. 43,688 mn, up 9% over last year.
- Research & Development (R&D) investments for the quarter stood at Rs. 3,225 mn (7.4% of revenues).
- EBITDA for the quarter was Rs. 11,461 mn, up 41% YoY. EBITDA margin for the quarter stood at 26.2%, an improvement of 580 bps on a YoY basis.
- Net Profit for the quarter was Rs. 8,007 mn, up 53% YoY.
- Capex (organic) for the quarter was Rs. 2,162 mn.
H1 FY24 Highlights
- Revenue from operations at Rs. 95,084 mn, up 19% over last year.
- Research & Development (R&D) investments stood at Rs. 6,464 mn (6.8% of revenues).
- EBITDA was Rs. 26,514 mn, up 61% YoY. EBITDA margin stood at 27.9%, an improvement of 720 bps over the previous year.
- Net Profit was Rs. 18,876 mn, up 81% YoY.
- Capex (organic) for the half year was Rs. 4,365 mn.
Consolidated Financial Results
Rs. mn Q2 FY24 Q2FY23 % Gr. y-o-y Q1 FY24 % Gr. q-o-q
Revenue from Operations 43,688 40,055 9.1% 51,396 -15.0%
EBITDA 11,461 8,153 40.6% 15,053 -23.9%
EBITDA margin (%) 26.2% 20.4% 29.3%
PBT 10,072 6,428 56.7% 13,292 -24.2%
Net Profit 8,007 5,225 53.2% 10,869 -26.3%
Rs. mn H1 FY24 H1 FY23 % Gr. y-o-y
Revenue from Operations 95,084 79,698 19.3%
EBITDA 26,514 16,483 60.9%
EBITDA margin (%) 27.9% 20.7%
PBT 23,364 13,238 76.5%
Net Profit 18,876 10,408 81.4%
Our Q2 FY24 result represents stable growth in our key businesses, as well as strong profitability. We are on track to meet our growth objectives for the year. Going ahead, differentiated launches in the US, in addition to a rebound in India business growth which was constrained by delayed seasonality, will be critical drivers. We anticipate sustained momentum in profitability and aim for EBITDA margins of more than 24% in the current fiscal year.
– Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited
Q2 FY24 Business-wise Sales Performance (Consolidated)
Rs. mn Q2 FY24 Q2 FY23 % Gr. YoY Q1 FY24 % Gr. QoQ
India Geography: 17,693 16,875 4.8% 19,206 -7.9%
Formulations 13,341 12,648 5.5% 12,270 8.7%
Consumer Wellness 4,352 4,227 3.0% 6,936 -37.3%
US Formulations 18,648 17,084 9.2% 24,541 -24.0%
EM & Europe Formulations 4,504 3,849 17.0% 4,893 -8.0%
APIs 1,402 1,117 25.5% 1,389 0.9%
Alliances & Others 339 501 -32.3% 499 -32.1%
Consolidated Revenues 42,586 39,426 8.0% 50,528 -15.7%
H1 FY24 Business-wise Sales Performance (Consolidated)
Rs. mn H1 FY24 H1 FY23 % Gr. YoY
India Geography: 36,899 35,042 5.3%
Formulations 25,611 23,899 7.2%
Consumer Wellness 11,288 11,143 1.3%
US Formulations 43,189 32,676 32.2%
EM & Europe Formulations 9,397 7,618 23.4%
APIs 2,791 2,341 19.2%
Alliances & Others 838 978 -14.3%
Consolidated Revenues 93,114 78,655 18.4%
Q2 FY24 Business Updates
India Geography
- Comprises of Formulations as well as Consumer Wellness businesses and accounted for 42% of consolidated revenues.
- Registered revenues of Rs. 17,693 mn, up 5% y-o-y.
Formulations business
- Registered revenues of Rs. 13,341 mn, up 6% y-o-y.
- Branded formulations business grew in high single digit adjusting for NLEM impact and was partly affected by delay in acute season.
- The business accounted for 32% of consolidated revenues.
- Gained market share and improved ranking in anti-diabetic and respiratory therapies during the quarter on a y-o-y basis (Source: IQVIA Jul – Sep 23 data).
- On the super specialty front, retained leadership position in the Nephrology segment while in the Oncology space, remained the fastest growing company.
Consumer Wellness business
- Registered revenues of Rs. 4,352 mn, up 3 % y-o-y. Consumer Wellness business accounted for 10% of consolidated revenues.
- Personal care segment, which comprises of Nycil and EverYuth brands, registered robust growth driven by favorable season in many parts of the country.
US formulations business
- Registered revenues of Rs. 18,648 mn, up 9% y-o-y and down 24% q-o-q. The business accounted for 44% of consolidated revenues.
- In constant currency terms, the business registered revenues of US$ 225 mn. • Launched 8 new products during the quarter.
- New launches include Indomethacin suppository which was granted 180 days of Competitive Generic Therapy (CGT) exclusivity and Plerixafor injection which was a Day 1 launch.
- Filed 4 ANDAs and received approval for 9 ANDAs during the quarter.
Emerging Markets (EM) and Europe formulations business
- Registered revenues of Rs. 4,504 mn, up 17% YoY. The business accounted for 10% of consolidated revenues.
- The business continued to deliver healthy growth with all major markets contributing to the growth during the quarter.
API business
- Registered revenues of Rs. 1,402 mn, up 26% y-o-y. The business accounted for 3% of consolidated revenues.
Alliances & Others
- Registered revenues of Rs. 339 mn, down 32% y-o-y. The business accounted for 1% of consolidated revenues.
Updates on Operations and Compliance
- Received Establishment Inspection Reports (EIR) from the USFDA for the inspections of Oral Solid Dosage (OSD) facilities I and II located in Ahmedabad SEZ and Biologics fill-finish facility located at Zydus Biotech Park in Changodar (near Ahmedabad).
Updates on Innovation Pipeline
NCE: ZYIL1
- Initiated Phase II clinical trials in patients with Amyotrophic Lateral Sclerosis (ALS).
- ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset.
NCE: PCSK9 inhibitor
- Received approval from the CDSCO to initiate Phase I clinical trials to evaluate the safety and tolerability. The molecule will be administered subcutaneously in healthy human volunteers.
- Dyslipidemia patients with high LDL cholesterol are at a high risk of atherosclerotic cardiovascular disease (ASCVD), such as heart attack and stroke.
- This PCSK9 inhibitor will regulate the levels of LDL receptors, which are responsible for the uptake and clearance of cholesterol from the blood.
Biotech R&D
- Completed clinical trials for one monoclonal antibody (mAb) and completed recruitment of patients for clinical trials for another mAb.
- Received regulatory approval to initiate Phase III clinical trials for one more product.
Specialty Initiatives
- Received final approvals from the USFDA for two New Drug Applications (NDAs) viz. Sitagliptin tablets (ZITUVIOTM)and Sitagliptin and Metformin IR tablets (ZITUVIMETTM) in the area of metabolic disorder management.
- Filed one more NDA viz. Sitagliptin and Metformin ER tablets in the area of metabolic disorder management.
Other Updates
- Acquired UK headquartered LiqMeds Group of companies which has the capabilities and specialization in development, manufacturing and supply of oral liquid products for global markets.
- LiqMeds has a rich pipeline of differentiated products which includes many 505(b)(2) and FTF/ FTM products.
- The acquisition is in line with the strategy to expand the presence in the specialty space and offer novel solutions to satisfy unmet medical needs.
Q2 FY24 Earnings Call Details
The Company will host its post results earnings call at 4:00 p.m. IST on 7th November, 2023 during which the leadership team will discuss the financial performance and address questions from the participants.
